Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

HER2DX Could Aid Chemotherapy Decision-Making in HER2+ Early-Stage Breast Cancer

November 5th 2025

HER2DX low-risk scores were associated with improved 10-year RFS and OS outcomes in older patients with HER2-positive early-stage breast cancer.

Dr Gupta on Avelumab Maintenance in Urothelial Carcinoma With/Without Diabetes Mellitus

November 5th 2025

Shilpa Gupta, MD, discusses data from a subgroup analysis of the phase 3 JAVELIN Bladder 100 and future questions surrounding the use of avelumab maintenance in this setting.

Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors

November 5th 2025

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

Dr Colombo on the Rationale for Evaluating Pembrolizumab Plus Paclitaxel With/Without Bevacizumab in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses the rationale for evaluating pembrolizumab plus weekly paclitaxel with/without bevacizumab in recurrent PROC.

JAK Inhibitors Expand Treatment Options in Polycythemia Vera and Myelofibrosis

November 4th 2025

Akriti Jain, MD, highlights the evolving role of JAK inhibitors in managing polycythemia vera and myelofibrosis and efforts to optimize treatment sequencing.

Adjuvant Ribociclib Plus AI Therapy Shows More Pronounced iDFS Benefit After 5 Years in HR+, HER2-Negative Early Breast Cancer

November 4th 2025

Sara A. Hurvitz, MD, FACP, unpacks data with adjuvant ribociclib plus endocrine therapy from the 5-year prespecified analysis of the NATALEE trial.

Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R Myeloma

November 4th 2025

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.

Oncology Experts Dive Into Top Data From ESMO 2025

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs

November 3rd 2025

Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma

November 3rd 2025

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.

Lifileucel Displays Antitumor Activity in Advanced Nonsquamous NSCLC

November 3rd 2025

Lifileucel was deemed safe and active in patients with previously treated, advanced nonsquamous NSCLC without certain actionable genetic mutations.

Evolving Role of TKIs and Antibody-Based Strategies Refines Ph-Positive ALL Management

November 3rd 2025

Wendy Stock, MD, discusses how TKI-based, chemotherapy-free regimens are advancing Ph-positive ALL care toward durable, treatment-free remission.

FDA Approval of Zongertinib Marks a Targeted Advancement for Patients With HER2-Mutant NSCLC

November 3rd 2025

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

Revisit Every OncLive On Air Episode From October 2025

November 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in October 2025.

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

October 31st 2025

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Cemiplimab Receives Reimbursement in Seven Provinces for NSCLC, Basal Cell Carcinoma

October 31st 2025

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

Mirvetuximab Soravtansine Receives Positive Reimbursement Recommendation From Canada’s Drug Agency for Platinum-Resistant Ovarian Cancer

October 31st 2025

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Personalized, Patient-Centered Strategies Shape the Evolving Management of Metastatic Pancreatic Cancer

October 31st 2025

Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

Dr Elias on Outcomes With Niraparib Maintenance Therapy in Ovarian Cancer

October 31st 2025

Kevin Elias, MD, discusses efficacy data from the PRIMA and NOVA trials evaluating niraparib as maintenance therapy in ovarian cancer.

FDA Sets PDUFA Date for LNTH-2501 in Imaging of SSTR+ Neuroendocrine Tumors

October 30th 2025

The FDA set a March 29, 2026, PDUFA date for LNTH-2501, a PET imaging agent targeting SSTR-positive neuroendocrine tumors.